Daniel O’Connell, MD, PhD, joined Novo Holdings in 2022 as Partner in the Venture Investments team, based in the San Francisco office.

Prior to joining Novo Holdings, Daniel was Head of Equity and Venture Capital at BMS, where he was responsible for managing all equity investments and LP positions on behalf of BMS. Daniel has been an investor focused on private biotech opportunities at Arix Bioscience and OrbiMed, and started his career in operations at Arisaph Pharmaceuticals.

Daniel completed his undergraduate degrees at MIT and obtained his MD and PhD from Tufts University.